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Persistent activation of the signal transducer and activator of transcription 3 (STAT3) signalling has been linked to oncogenesis and
the development of chemotherapy resistance in glioblastoma and other cancers. Inhibition of the STAT3 pathway thus represents an
attractive therapeutic approach for cancer. In this study, we investigated the inhibitory effects of a small molecule compound known
as LLL-3, which is a structural analogue of the earlier reported STAT3 inhibitor, STA-21, on the cell viability of human glioblastoma
cells, U87, U373, and U251 expressing constitutively activated STAT3. We also investigated the inhibitory effects of LLL-3 on U87
glioblastoma cell growth in a mouse tumour model as well as the impact it had on the survival time of the treated mice. We observed
that LLL-3 inhibited STAT3-dependent transcriptional and DNA binding activities. LLL-3 also inhibited viability of U87, U373, and
U251 glioblastoma cells as well as induced apoptosis of these glioblastoma cell lines as evidenced by increased poly (ADP-ribose)
polymerase (PARP) and caspase-3 cleavages. Furthermore, the U87 glioblastoma tumour-bearing mice treated with LLL-3 exhibited
prolonged survival relative to vehicle-treated mice (28.5 vs 16 days) and had smaller intracranial tumours and no evidence of
contralateral invasion. These results suggest that LLL-3 may be a potential therapeutic agent in the treatment of glioblastoma with
constitutive STAT3 activation.
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The signal transducer and activator of transcription (STAT)
protein family is a group of primarily cytosolic proteins that play
an important role in relaying signals from growth factors
and cytokines (Zhong et al, 1994a, b; Bromberg and Darnell,
2000; Shen et al, 2004). Several STATs have been associated with
the induction and survival of cancer cells, however, STAT3 is
especially prominent in this regard. The signal transducer and
activator of transcription 3 is widely expressed in normal cells but
its transient activation is strictly regulated by protein inhibitors of
STATs (PIAS), SH2-containing tyrosine phosphatases (SHP1 and
SHP2), and suppressor of cytokine signalling/extracellular signal-
regulated kinase (SOCS/ERK). In several human cancers including
glioblastoma, a dysregulation of the above mechanisms leads to
constitutive activation of STAT3 (Rahaman et al, 2005). Consti-
tutive STAT3 activation has been linked to cancer initiation,
proliferation, promotion of angiogenesis and inhibition of
apoptosis. There is evidence that constitutively active STAT3 can
transform non-malignant cells into malignant cells (Huang et al,
2005). Activation of STAT3 has also been shown to enhance
immune tolerance in glioblastoma, enabling cancer cells to evade
immune surveillance (Hussain et al, 2007).
Given these oncogenic functions of STAT3, directly targeting the
constitutive activation of the STAT3 pathway represents a potential
therapeutic option in cancers with constitutively active STAT3.
Activation of STAT3 occurs when it is phosphorylated at the
Tyr-705 residue. This leads to dimerisation of STAT3 and subsequent
transcription to the nucleus where further activation promotes
DNA binding and translation of target genes (Carballo et al, 1999).
Earlier findings have shown that STA-21, a polyphenol, can inhibit
STAT3 activities and induce cell death in breast cancer cells
(Song et al, 2005). Using a structure-based strategy, we selected
a structural analogue of STA-21 termed as LLL-3 (Figure 1A), for
further evaluation. Computer models with docking simulation
showed that LLL-3 (Figure 1A) has a similar binding mode as
STA-21, however, the smaller size of LLL-3 (molecular weight of
266 g mol1 compared with the 306 g mol1 of STA-21) would have
an enhanced ability to transport into the cell.
Glioblastoma is the most common type of primary malignant
brain cancer. Despite advances in surgical interventions, chemo-
therapy and radiation therapy, prognosis remains very poor, and
current therapies are associated with significant side effects (Ries
et al, 2004). Many clinical cases of glioblastoma and glioblastoma
cell lines express constitutively activated STAT3 (Rahaman et al,Revised 30 September 2008; accepted 28 October 2008
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2002; Iwamaru et al, 2006). Studies have shown that inhibition of
STAT3 reverses immune tolerance in malignant glioma cells
(Hussain et al, 2007). These circumstances necessitate the search
for novel targeted and more effective therapies for these cancers
and STAT3 signalling represents an attractive target.
Here we report the inhibitory activity of LLL-3 on glioblastoma
cell viability. We show that cell death occurs via apoptosis and also
show that treating mice with intracranial human glioblastoma
leads to a decrease in tumour size, invasiveness and prolongs their
overall survival.
MATERIALS AND METHODS
Computational binding studies of LLL-3
In recent years, computational docking methods have been
increasingly used to predict the binding of a ligand to a specific
site of a protein structure. AutoDock4 is a docking program with a
graphical tools package that uses a scoring function, also known as
a force field, to search through a conformational landscape of a
ligand to calculate the free energy of binding to a target site of
a macromolecule. AutoDock4 determines the conformations of a
ligand in the binding site while minimising the total energy of the
protein–ligand complex, computed according to the following
equations (Huey et al, 2007):
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DG refers to the change in free energy of Van der Waals, hydrogen
bonding, electrostatic, desolvation, and torsional forces. The small
molecule LLL-3 was docked using the Lamarckian genetic
algorithm and most default parameters. The docking procedure
involved the preparation of the ligand and macromolecule,
the assignment of Gasteiger charges, and the identification of
the torsional root and the two rotatable bonds of the ligand. An
AutoGrid map was then pre-computed for all atom types in the
ligand set. After 10 million energy evaluations were completed, all
the resulting conformations of the ligand in the binding pocket of
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Figure 1 (A) AutoDock4 molecular surface visualisation of the STAT3 SH2 domain (residues 582–702) secondary structure ribbon, with selected
binding pocket residues and predicted correct docking conformation of ligand LLL-3 (chemical structure insert), rendered by ball-and-stick models, in the
target PTR-binding pocket of STAT3. The small molecule LLL-3, an analogue of STA-21, forms two hydrogen bonds with specific residues ARG609 and
ILE634. (B) The inhibitory effect of STAT3 DNA binding activity in U373 and MDA-MB-231 cells and STAT3 transcriptional activity in MDA-MB-231 cells by
LLL-3. Statistical significance (Po0.05) relative to the untreated (in MDA-MB-231 cells) or DMSO (in U373 cells) is designated by an asterisk.
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the macromolecule were clustered into groups according to
their conformations and the docking results based on the
predicted correct docking pose of the ligand. The AutoDock4
docking results with LLL-3 produced two major clusters with
different binding conformations of the ligand. The correct binding
mode is the second largest cluster, which has a 6.8 kcal mol1 free
energy of binding and comprises 10% of all the possible docking
conformations.
Cell lines
U251 and U373 human glioblastoma cell lines were kindly
provided by Dr Sean Lawler (Comprehensive Cancer Center, the
Ohio State University). U87 human glioblastoma cells were
purchased from the American Type Culture Collection (Manassas,
VA, USA). All cancer cells were maintained in Dulbecco’s modified
Eagle’s medium (DMEM) supplemented with 10% foetal bovine
serum, penicillin (100 U ml1) and streptomycin (100 U ml1).
Normal human bladder smooth muscle cells were purchased from
the Cambrex Corporation (East Rutherford, NJ, USA) and were
grown in the media recommended by the company. The cell
culture incubator was set at 371C and aired with 5% CO2.
Reconstitution of LLL-3
LLL-3 was synthesised in Dr Pui-Kai Li’s laboratory (School of
Pharmacy, The Ohio State University). The powder was dissolved
in sterile DMSO to make a 20 mM stock solution. The stock
solution was stored at 201C and thawed just before usage.
Establishment of STAT3-dependent luciferase reporter in
MDA-MB-231 cancer cells
Plasmid pLucTKS3 contains seven copies of STAT3-binding site in
TK minimal promoter (Turkson et al, 1998) and its activation
specifically depends on STAT3 status in the cell environment.
pLucTKS3 luciferase reporter plasmid was transfected into
MDA-MB-231 cancer cell line using Lipofectamine 2000 reagent.
The stable clones, which showed high luciferase activity, were
selected for screening STAT3 inhibitors. The selected clones were
exposed to LLL-3 at a final concentration of 20 mM for 48 h, and
luciferase activity was measured by using a Promega Luciferease
kit (Madison, WI, USA) following manufacturer’s instructions.
STAT3 DNA binding activity
U373 glioblastoma and MDA-MB-231 cancer cells were treated
with 20 –50 mM LLL-3 for 48 h. In all, 2 pmol of biotinylated STAT3
wild-type consensus DNA binding sequences was added to
5–10 mg of U373 or MDA-MB-231 nuclear extract. TransFactor
Universal STAT3 Specific Kit (Clontech Laboratories Inc.,
Mountain View, CA, USA; catalogue no. 631958) that permits
flexible assay design for the rapid identification of STAT3
transcription factor DNA binding in cell extracts using an ELISA
(enzyme-linked immunosorbent assay) format was used to
determine the STAT3 DNA binding activity.
Cell viability assay
A total of 5000 cells of U87, U251, and U373 were seeded per well
in triplicates in 96-well plates. Plates were then incubated
overnight. The next day serial dilutions of LLL-3 were prepared
to achieve desired concentrations. Untreated and DMSO-treated
cells were seeded in triplicates and served as controls. Cells were
incubated at 371C for 72 h. 3-(4,5-Dimethylthiazolyl)-2,5-diphe-
nyltetrazolium bromide (MTT) viability assays were carried out
after 72 h according to the manufacturer’s protocol (Roche
Diagnostics, Mannheim, Germany). 3-(4,5-Dimethylthiazolyl)-2,5-
diphenyltetrazolium bromide assay measures cell viability based
on mitochondrial conversion of MTT from a soluble tetrazolium
salt into an insoluble formazan precipitate. After dissolving in N,N-
dimethylformamide, it can be quantified by spectrophotometry.
All experiments were repeated three times.
Immunofluorescence staining for apoptosis
Immunostaining was performed as described earlier (Chen et al,
2007). Cleaved-caspase-3 (Asp175) antibody was purchased from
Cell Signaling Technologies Inc. (Danvers, MA, USA). Secondary
goat anti-rabbit IgG(Hþ L) Alexa FluoR 594 antibody was
purchased from Invitrogen (Carlsbad, CA, USA). U87, U373, and
normal human bladder smooth muscle cells were plated in six-well
plates containing sterile cover slips and allowed to grow overnight.
They were then treated with 20 mM LLL-3 or DMSO. Controls with
no treatment were also performed. After 48 h, the cells were fixed
using methanol/acetone (1 : 1 volume) for 30 min followed by three
washes with 1 PBS. After the third wash, cover slips were
transferred to a new six-well plate. Immunofluorescence staining
for cleaved caspase-3 (Asp175) was performed. Nuclei were stained
with DAPI. The fluorescence and phase contrast photographs were
documented using LEICA OM-IRB inverted fluorescent micro-
scope (Leica Microsystems Inc., Bannockburn, IL, USA) with
an attached diagnostic RI-SE6 monochrome digital camera
(Diagnostic Instrument Inc., Sterling Heights, MI, USA).
Western blot analysis
U87, U251, and U373 glioblastoma cells were plated in 10 cm sterile
dishes and left to grow overnight. They were then treated with
20mM LLL-3 or DMSO. Control plates with no treatment were also
performed. After 48 h, cells were harvested at 41C in cold harvest
buffer and spun down at 41C at 3000 r.p.m. for 5 min. Cell pellets
were lysed in cold RIPA lysis buffer containing protease inhibitors.
Protein concentrations were determined using the BCA protein
assay as per the manufacturer’s protocol (PIERCE Biotechnologies,
Rockford, IL, USA). Cleaved-poly (ADP-ribose) polymerase
(PARP) (Asp214) antibodies were purchased from Cell Signaling
Technologies Inc. (Danvers, MA, USA). Western blot analysis was
performed as per established procedure. Membranes were also
probed with an antibody to GAPDH to ascertain protein loading of
cellular proteins. Membranes were analysed with enhanced
chemiluminescence plus reagents and scanned with the Storm
scanner (Amersham Pharmacia Biotech Inc., Piscataway, NJ, USA).
Animal subjects and intracranial studies
Female athymic nude mice (nu/nu) were purchased from the
animal production area of The National Cancer Institute-Frederick
Cancer Research and Development Center (Frederick, MD, USA).
All animal manipulations were carried out in accordance with
institutional guidelines under approved protocols. Actively grow-
ing U87 glioblastoma cells were injected at a concentration of
1 105 cells in 5 ml. Mice were anaesthetised with ketamine/
xylazine mixture (114 : 17 mg kg1) and a 0.5-mm burr hole was
made 1.5–2 mm right of the midline and 0.5–1 mm posterior to
the coronal suture through a scalp incision. Stereotaxic injection
used a 10 ml syringe (Hamilton Co., Reno, NV, USA) with a 30-
gauge needle, inserted through the burr hole to 3 mm, mounted on
a Just For Micet stereotaxic apparatus (Harvard Apparatus) at a
rate of 2 ml min1. Three days later, when microscopic tumours
grew and animals were asymptomatic, the mice were randomly
split into two groups of five animals. One group received a single
intratumoural injection of 50 mg kg1 of LLL-3 administered
stereotaxically. Animals losing 420% of their body weight or
having trouble ambulating, feeding, or grooming were killed.
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Magnetic resonance imaging
Magnetic resonance imaging (MRI) was performed on a 7T small
animal system (Brucker Biospin, Ettlingen, Germany), equipped
with an actively shielded gradient set, with a maximum gradient
strength of 400 mT m1. Signal excitation and reception was
accomplished with a 25-mm Litz RF coil. Conventional T2-weighted
RARE images (TE¼ 60 ms, TR¼ 3000 ms, slice thickness¼ 1 mm,
matrix¼ 256 256) were acquired in coronal (FOV¼ 2.5
2.5 cm2) and axial (FOV¼ 2.2 2.2 cm2) orientations to assess
differences in anatomy.
Tumour volume calculations
Tumour volumes were calculated using ImageJ. Contours were
drawn on the T2-weighted images, based on image pixel
intensities. In brief, the tumours were manually outlined using
T2 data with freehand selection tool or the polygon selection tool.
Then the ‘measure’ command generated an area for the region on
the slice. The area was converted to volume by multiplying it times
a conversion factor (converted to the actual voxel size), and the
known width of the slices (1 mm). This was carried out for each
slice, and then the separate slice volumes were added together for a
total volume.
Statistical analysis
GraphPad Prism (version 5, GraphPad Software Inc., San Diego,
CA, USA) was used for statistical analysis. Survival curves were
generated by Kaplan–Meier method. The log-rank test was used
to compare the distributions of survival times, and a P-value of
o0.05 was considered significant. Microsoft excel was used to
analyse the cell viability data. Results were presented as bar charts
with error bars as needed.
RESULTS
LLL-3 inhibits STAT3-dependent transcriptional and DNA
binding activities
We utilised a structure-based strategy to select LLL-3 (Figure 1A)
as a STA-21 structural analogue and docking simulation showed a
similar binding mode as STA-21. Because transcription and DNA
binding activities are key functions for constitutively active STAT3
signalling in the promotion of oncogenesis, we examined whether
LLL-3 could inhibit both STAT3’s transcription and DNA binding
activities. Our results show that LLL-3 inhibits STAT3-specific
DNA binding activity in U373 glioblastoma cells and MDA-MB-231
breast cancer cells (Figure 1B) as well as inhibits STAT3-dependent
transcription activity in luciferase assays in MDA-MB-231 breast
cancer cells (Figure 1B).
Inhibition of GBM cell viability by LLL-3
U87, U251, and U373 human GBM cells, which express constitu-
tively active STAT3, were treated with 10– 40 mM of LLL-3. Our
results showed that significantly decreased cell viability (o25%)
was observed when compared with untreated cells and DMSO-
treated cells. At a concentration of 30mM of LLL-3, cell viability
decreased to o10% in U87, U251, and U373 glioblastoma cells
(Figure 2). The decrease in cell viability was also visible through
phase contrast microscopy as there are fewer cells when treated
with LLL-3 (Figure 4).
LLL-3 induced poly (ADP-ribose) polymerase cleavage in
glioblastoma cells
We next examined whether the inhibition of cell viability could
be due to the induction of apoptosis in these glioblastoma
cells. U87, U251, and U373 glioblastoma cells treated with 20mM
of LLL-3 showed high levels of cleaved PARP (Asp214)
whereas little PARP cleavage was observed in DMSO-treated and
untreated cells as measured with western blot analysis (Figure 3).
Analysis for GAPDH showed similar total protein amounts of
GAPDH in the LLL-3, DMSO-treated and untreated samples. These
results indicate that LLL-3 can induce apoptosis in these
glioblastoma cells, which may account for the reduction of cell
viability.
LLL-3 induced caspase-3 cleavage
We also examined whether LLL-3 could induce caspase-3 cleavage,
which contributes to the induction of apoptosis. U373 glioblasto-
ma cells were treated with LLL-3, resulting in high levels of cleaved
caspase-3 as measured by immunofluorescence staining. In
contrast, DMSO-treated and untreated cells had very little cleaved
caspase-3 (Figure 4). We also observed the induction of caspase-3
cleavage by LLL-3 in U87 human glioblastoma cells (Figure 4).
However, the induction of cleaved caspase-3 was not observed in
normal human bladder smooth muscle cells (data not shown),
which do not express constitutively active STAT3.
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Figure 2 MTT cell viability assays in U87, U251, and U373 glioblastoma cells. Figure shows MTT cell viability after treatment with 20 and 30 mM of LLL-3
and DMSO relative to untreated cells for 72 h. In U87, U251, and U373 glioblastoma cells, there is a decrease in viability after exposure to 20 mM LLL-3.
There is further decrease in viability with a treatment concentration of 30–40 mM. Statistical significance (Po0.05) relative to the untreated (NT) is
designated by an asterisk.
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Intracranial tumour size and tumour infiltration
Unilateral intracranial tumours were established in athymic nude
mice and randomly treated with LLL-3 or control treated. Tumours
in LLL-3-treated animals were significantly smaller and less hyper
intense than tumours in control animals (Figures 5). We also
detected distortion of the midline with tumour invasion into the
contralateral side in control animals that was clearly not detected in
the LLL-3-treated mice. Average tumour volume was calculated
from sequential MRI images by analysis of individual pixel
intensities to more accurately define tumour boundaries, and
estimated to be 73.2 mm3 for control animals and 17.0 mm3 for LLL-
3-treated animals, further showing that LLL-3 significantly contains
tumour growth in an intracranial glioblastoma mouse model.
Increased survival in LLL-3-treated animals
Animals receiving LLL-3 showed an initial small decrease in body
weight (5–10%), which was quickly compensated for within three
days following LLL-3 injection, and remained healthy for the
duration of the study. The median survival time in the untreated and
vehicle (DMSO)-treated animals were 17.5 and 16 days, respectively,
compared with 28.5 days in the LLL-3-treated animals (P¼ 0.03)
(Figure 6). Prolonged survival time in LLL-3 treatment group was
190% compared with the control group. The increase in survival
correlated with the tumour area as detected by MRI (Figure 6).
DISCUSSION
The signal transducer and activator of transcription 3 is an
oncogenic protein that is capable of inducing tumours and
enhancing cancer proliferation. In its inactive form, it is found
predominantly in the cytoplasm. Phosphorylation at Tyr-705 causes
it to dimerise and translocate to the nucleus where it binds to
specific promoter sequences on its target genes. Blocking signalling
to STAT3 by dominant-negative (DN) STAT3 mutant or antisense
STAT3 oligonucleotides inhibits cancer cell growth, showing that
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Figure 4 Immunofluorescence staining for cleaved caspase-3 in U373 and U87 glioblastoma cells after treatment for 48 h. Figure shows DAPI and red
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STAT3 is crucial to the survival and growth of tumour cells (Kaptein
et al, 1996; Aoki et al, 2003; Calvin et al, 2003). Constitutive STAT3
signalling participates in oncogenesis by stimulating cell prolifera-
tion, mediating immune evasion, promoting angiogenesis, and
resistance to apoptosis induced by conventional therapies (Shen
et al, 2001; Buettner et al, 2002; Real et al, 2002; Wang et al, 2004).
There have been several strategies to inhibit the STAT3 pathway as
a therapeutic approach in treating cancers, such as by using small
molecules and DNA decoys (Lui et al, 2007). In addition, other
inhibitors of STAT3 have also been reported including Cucurbitacin
Q, which inhibits STAT3 phosphorylation (Sun et al, 2005), E804
that inhibits both Src and STAT3 (Nam et al, 2005); Stattic (Schust
et al, 2006) and S3I-201 (Siddiquee et al, 2007), which inhibit STAT3
dimerisation, and SD-1029, which inhibits STAT3 nuclear translo-
cation (Duan et al, 2006).
One difficulty with targeting proteins directly is that the targeted
proteins may often also control other vital pathways sometimes
leading to severe unwanted effects. LLL-3, a structural analogue
of STA-21 with a smaller molecular weight and the added benefit
of being easier to synthesise, may be a more suitable agent for
targeting cancer cells with constitutively activated STAT3 pathway.
In this study, we evaluated the inhibitory efficacy of LLL-3 in
human GBM cells. Our results show that, LLL-3 inhibits STAT3
activities, inhibits cell viability, and induces apoptosis in U87,
U251, and U373 glioblastoma cells. We further show that LLL-3
inhibits tumour growth and inhibits tumour invasiveness as well as
prolongs survival in an intracranial U87 glioblastoma xenograft
mouse model. These results suggest that inhibition of STAT3
pathway may be an effective therapeutic approach for treating
human glioblastoma.
Given that the STAT3 pathway may be necessary for renewal in
some embryonic stem cells (Niwa et al, 1998), there is legitimate
concern that indiscriminate inhibition of the STAT3 pathway may
lead to side effects of some stem cells. However, as STAT3
phosphorylation in normal cells is transient, LLL-3 would likely
have little effect on the proliferation of normal cells as suggested by
its effect on normal bladder smooth muscle cells. Furthermore,
studies using normal mouse fibroblasts showed that disrupting
STAT3 signalling has much less profound effect in normal human
and murine cells (Catlett-Falcone et al, 1999; Niu et al, 1999;
Bowman et al, 2001; Burke et al, 2001; Song et al, 2005), suggesting
that blocking STAT3 signalling may not be grossly toxic. Based on
our findings, LLL-3 appears to be a potential therapeutic agent for
human glioblastoma cells and possibly other tumours that have
constitutively active STAT3. In addition to its apoptotic effects it
may potentially render cancers more susceptible to other cytotoxic
agents. It should be of interest to further explore the possibility of
using LLL-3 as a potential agent for human glioblastoma treatment.
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Figure 5 MRI image evaluation of U87 orthotopic glioblastoma model showed large tumours in the right frontal cortex of untreated control animals:
midline shift was particularly evident (top row); LLL-3-treated animals showed tumours that were significantly smaller with decreased hyperintensity and no
evidence of midline shift (bottom row). Volumetric analysis of the average tumour volume was estimated to be 17.2 mm3 for the untreated control mice and
17.0 mm3 for the LLL-3-treated mice.
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Figure 6 Kaplan–Meier survival analysis. Survival of mice with
established brain tumours derived from U87 glioblastoma cells injected
intracranially with 50 mg kg1 of LLL-3 three days after implantation (n¼ 5).
Control mice with established brain tumours derived from U87
glioblastoma cells received no treatment (untreated control (n¼ 5)).
Survival was measured from the day of intracranial implantation of U87
glioblastoma cells. The median survival time of untreated control and
DMSO vehicle-treated mice were 17.5 and 16 days, respectively whereas
the LLL-3-treated mices’ survival was significantly increased to 28.5 days.
The log-rank test was used to assess the statistical differences in survival
among the two groups; P¼ 0.03.
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